AD80 HAS HIGHER POTENCY COMPARED TO CLINICALLY USED FLT3 INHIBITORS IN FLT3-ITD AML CELLS
LBL Mirandaa, NO Rossinib, K Limac, DA Pereir-Martinsd, JJ Schuringad, EM Regoc, F Trainae, MVB Diasb, JA Machad-Netoa
a Department of Pharmacology, Institute of Biomedical Sciences, Universidade de São Paulo (USP), São Paulo, Brazil
b Department of Microbiology, Institute of Biomedical Sciences, Universidade de São Paulo (USP), São Paulo, Brazil
c Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, Brazil
d Department of Experimental Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
e Department of Medical Imaging, Haematology, and Oncology, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, Brazil
Lido
939
Vezesque se leu este artigo
364
Total PDF
575
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 15 | 12 | 27 |
| 2025 5 | 47 | 12 | 59 |
| 2025 4 | 33 | 11 | 44 |
| 2025 3 | 50 | 11 | 61 |
| 2025 2 | 38 | 22 | 60 |
| 2025 1 | 25 | 15 | 40 |
| 2024 12 | 23 | 19 | 42 |
| 2024 11 | 24 | 15 | 39 |
| 2024 10 | 32 | 18 | 50 |
| 2024 9 | 45 | 24 | 69 |
| 2024 8 | 49 | 31 | 80 |
| 2024 7 | 28 | 24 | 52 |
| 2024 6 | 34 | 20 | 54 |
| 2024 5 | 37 | 23 | 60 |
| 2024 4 | 30 | 19 | 49 |
| 2024 3 | 21 | 12 | 33 |
| 2024 2 | 12 | 21 | 33 |
| 2024 1 | 4 | 2 | 6 |
| 2023 12 | 9 | 20 | 29 |
| 2023 11 | 10 | 26 | 36 |
| 2023 10 | 9 | 7 | 16 |
Mostrar tudo
